Evaluation of Antibiotic Appropriateness in Hospitalised Pediatric Pneumonia Patients at Ar-Rasyid Islamic Hospital Palembang: A Retrospective Gyssens-Based Study
DOI:
https://doi.org/10.35451/jfm.v9i1.3676Keywords:
antibiotics, Children, Gyssens Method, Hospital-Acquired Pneumonia, RationalityAbstract
Background: Pneumonia remains a leading cause of morbidity and mortality in children worldwide, particularly in developing countries, where irrational antibiotic use contributes to antimicrobial resistance and poorer clinical outcomes. Objective: This study aimed to evaluate the profile and rationality of antibiotic use in pediatric patients with hospital-acquired pneumonia at Ar-Rasyid Islamic Hospital, Palembang, during 2023-2024. Methods: A descriptive, observational, retrospective study was conducted on 100 medical records of pediatric patients aged 0-12 years who met the inclusion criteria; rationality was assessed using the Gyssens method. Results: The majority of patients are male (63%), with infants under 1 year of age comprising the largest age group (76%). The most frequently used antibiotic is injectable ceftazidime (49.40%). Gyssens' analysis reveals that only 35% of antibiotic prescriptions are classified as rational (Category 0), while 33% show inappropriate dosing (Category IIa), 10% are administered for too long (Category IIIa), and 22% for too short a duration (Category IIIb). Conclusion: These findings indicate that the rationality of antibiotic use in pediatric hospital-acquired pneumonia patients at this institution remains suboptimal, with dosing irregularities and inappropriate duration of therapy as the predominant issues. Implementation of an evidence-based Antimicrobial Stewardship Program is therefore essential to improve prescribing practices and reduce the risk of antimicrobial resistance in this vulnerable population.
Downloads
References
[1]. Unicef. Pneumonia in Children Statistics. UNICEF DATA [Internet]. 2025 [cited 2026 Mar 30]. Available from: https://data.unicef.org/topic/child-health/pneumonia/
[2]. Langefeld K. Pneumonia Remains Leading Cause of Child Mortality. Global Initiative for Chronic Obstructive Lung Disease - GOLD [Internet]. 2025 Nov 12 [cited 2026 Apr 27]. Available from: https://goldcopd.org/pneumonia-remains-leading-cause-of-child-mortality/
[3]. Nguyen PTK, Robinson PD, Fitzgerald DA, Marais BJ. The dilemma of improving rational antibiotic use in pediatric community-acquired pneumonia. Front Pediatr. 2023 Feb 8;11. doi:10.3389/fped.2023.1095166
[4]. World Health Organization, editor. Guideline on management of pneumonia and diarrhoea in children up to 10 years of age. Geneva: World Health Organization; 2024. 1 p.
[5]. Lokida D, Farida H, Triasih R, Mardian Y, Kosasih H, Naysilla AM, et al. Epidemiology of community-acquired pneumonia among hospitalised children in Indonesia: a multicentre, prospective study. BMJ Open. 2022 Jun 21;12(6):e057957. doi:10.1136/bmjopen-2021-057957 PubMed PMID: 35728910; PubMed Central PMCID: PMC9214401.
[6]. Li Q, Zhou Q, Florez ID, Mathew JL, Shang L, Zhang G, et al. Short-Course vs Long-Course Antibiotic Therapy for Children With Nonsevere Community-Acquired Pneumonia. JAMA Pediatr. 2022 Dec;176(12):1199–207. doi:10.1001/jamapediatrics.2022.4123 PubMed PMID: 36374480; PubMed Central PMCID: PMC9664370.
[7]. World Health Organization. Antimicrobial resistance [Internet]. 2024 [cited 2026 Apr 27]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
[8]. Kok HC, Chang AB, Fong SM, McCallum GB, Yerkovich ST, Grimwood K. Antibiotics for Paediatric Community-Acquired Pneumonia: What is the Optimal Course Duration? Paediatr Drugs. 2025;27(3):261–72. doi:10.1007/s40272-024-00680-4 PubMed PMID: 39847251; PubMed Central PMCID: PMC12031807.
[9]. Attaianese F, Privato R, Montagnani C, Stivala M, Trapani S, Galli L, et al. Antibiotic optimization in hospitalized children with non-severe community-acquired pneumonia: lessons from an antimicrobial stewardship intervention (2022–2024). Front Pediatr. 2025 Nov 4;13:1660776. doi:10.3389/fped.2025.1660776 PubMed PMID: 41262920; PubMed Central PMCID: PMC12623335.
[10]. Lipsett SC, Hirsch AW, Bachur RG, Neuman MI. Interpretation of Antibiotic Trials in Pediatric Pneumonia. JAMA Netw Open. 2024 Feb 2;7(2):e2354470. doi:10.1001/jamanetworkopen.2023.54470 PubMed PMID: 38306101; PubMed Central PMCID: PMC10837740.
[11]. Limato R, Lazarus G, Dernison P, Mudia M, Alamanda M, Nelwan EJ, et al. Optimizing antibiotic use in Indonesia: A systematic review and evidence synthesis to inform opportunities for intervention. Lancet Reg Health Southeast Asia. 2022 May 26;2:100013. doi:10.1016/j.lansea.2022.05.002 PubMed PMID: 37383293; PubMed Central PMCID: PMC10305907.
[12]. Ciptaningtyas VR, Sumekar TA, Fauzia LP, Lestari ES, Farida H, Margawati A, et al. Community-acquired pneumonia in Indonesian children: insights into diagnosis, treatment compliance, and healthcare provider challenges. Arch Public Health. 2025 Dec 3;84:9. doi:10.1186/s13690-025-01795-x PubMed PMID: 41339952; PubMed Central PMCID: PMC12794261.
[13]. Farizi GRA, Gloria F, Dewi RM, Aldila S, Ramadhani CW, Busdha D, et al. Evaluation of Intravenous Antibiotic Use in Pediatric Pneumonia Patients Using ATC/DDD and Gyssens Methods at Primaya Hospital, Semarang. 2024.
[14]. Agustiana A, L AF, Arba M, Jabbar A, Suryani S, Akib NI. Evaluation of antibiotic use in pneumonia patients at bahteramas hospital using the gyssens method. Science Midwifery. 2025 Jul 26;13(3):793–801. doi:10.35335/midwifery.v13i3.1994
[15]. Efrilia - D, Carolia N, Mustofa S, Oktarlina RZ. . Metode Gyssens Sebagai Pilihan Utama Dalam Evaluasi Kualitatif Penggunaan Antibiotik di Indonesia. Medical Profession Journal of Lampung. 2023 Jan 31;13(2):14–22. doi:10.53089/medula.v13i2.526
[16]. Manan NE, Wiyono WI, Mpila DA. Evaluasi Penggunaan Antibiotik pada Pasien Pneumonia di Bangsal Pediatri. e-CliniC. 2025 Mar 17;13(2):189–95. Located at: Antibiotics use in pediatric patients with pneumonia. doi:10.35790/ecl.v13i2.61015
[17]. Zaevany TA, Adiana S, Rochjana AUH. Pola penggunaan antibiotik pada pasien pneumonia di instalasi rawat inap rumah sakit X Bekasi tahun 2023. Indonesian Journal of Health Science. 2025 Jul 24;5(4):881–6. doi:10.54957/ijhs.v5i4.1630
[18]. Monica C, S A, Dalilla S. DRP Evaluasi Drung Related Problems (DRPS) Antibiotik pada Pasien Pneumonia Rawat Inap Anak Rumah Sakit Umum Daerah Deli Serdang. Jurnal Farmasimed (JFM). 2021 Apr 29;3(2):63–8. doi:10.35451/jfm.v3i2.574
[19]. Widiastuti Z, Purwaningsih AEDA, Ulum AN. Antibiotic Use in Inpatients with Diarrhea in Children: A Quantitative Evaluation at Hospital X, Semarang Regency, 2023. Jurnal Farmasimed (JFM). 2025 Nov 13;8(1):213–9. doi:10.35451/s8qfqn40
[20]. Miller RAJ, Williams AP, Kovats S. Sex chromosome complement and sex steroid signaling underlie sex differences in immunity to respiratory virus infection. Front Pharmacol. 2023 Mar 30;14:1150282. doi:10.3389/fphar.2023.1150282
[21]. Empey KM, Fixman ED, Cormier S, Kolls JK, Piedimonte G. Editorial: Neonatal host immune responses to pulmonary infections. Front Immunol. 2023;14:1219844. doi:10.3389/fimmu.2023.1219844 PubMed PMID: 37292202; PubMed Central PMCID: PMC10246766.
[22]. Li Y, Wei M, Cui L, Huo X, Ma L, Tao R, et al. Respiratory pathogens in infants and young children with acute respiratory illness: a prospective cohort study, China, 2023-2024. Front Public Health. 2025;13:1548190. doi:10.3389/fpubh.2025.1548190 PubMed PMID: 40832017; PubMed Central PMCID: PMC12358494.
[23]. Panetti B, Bucci I, Di Ludovico A, Pellegrino GM, Di Filippo P, Di Pillo S, et al. Acute Respiratory Failure in Children: A Clinical Update on Diagnosis. Children (Basel). 2024 Oct 12;11(10):1232. doi:10.3390/children11101232 PubMed PMID: 39457197; PubMed Central PMCID: PMC11506303.
[24]. Yun KW. Community-acquired pneumonia in children: updated perspectives on its etiology, diagnosis, and treatment. Clin Exp Pediatr. 2024 Feb;67(2):80–9. doi:10.3345/cep.2022.01452 PubMed PMID: 37321577; PubMed Central PMCID: PMC10839192.
[25]. Agustina NN, Fitrianto A, Santosa Q, Naufalin R, Maulena U, Anjarwati DU. Assessing the Impact of Antimicrobial Stewardship on Antibiotic Rationality in a Tertiary Hospital Setting. Journal Of The Indonesian Medical Association. 2023;73(6):274–81. doi:10.47830/jinma-vol.73.6-2024-821
[26]. Sinto R, Limato R, Radiani SP, Huda MN, Surendra H, Praptiwi AW, et al. A nationwide mixed-methods study of gaps and barriers to implementation of antimicrobial stewardship programmes in hospitals in Indonesia. J Hosp Infect. 2024 Dec;154:77–87. doi:10.1016/j.jhin.2024.10.001 PubMed PMID: 39426628.
[27]. Suri N, Junando M, Afriyana R. A Comprehensive Evaluation of Antibiotic Usage: Establishing a Foundation for Effective Antimicrobial Stewardship. JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA. 2024 Dec 31;11(3):298–311. doi:10.20473/jfiki.v11i32024.298-311
[28]. Aprilina DA, Hutahaen TA, Zuhriyah A, Noer SS. Rationality Analysis of Antibiotic Use in Chronic Kidney Disease Patients at Dr. R. Sosodoro Djatikoesoemo Regional HospitalUsing the Gyssens Method. Jurnal Farmasimed (JFM). 2025 Nov 13;8(1):33–42. doi:10.35451/6xrbg306
[29]. Puzz L, Plauche EA, Cretella DA, Harrison VA, Wingler MJB. Evaluation of a Pediatric Community-Acquired Pneumonia Antimicrobial Stewardship Intervention at an Academic Medical Center. Antibiotics (Basel). 2023 Apr 19;12(4):780. doi:10.3390/antibiotics12040780 PubMed PMID: 37107141; PubMed Central PMCID: PMC10135107.
[30]. Widi ASRJP, Purwaningsih AEDA, Sari N. Evaluation Of Antibiotic Use In Diabetic Ulcer Patients Based On The Defined Daily Dose Method (DDD). Jurnal Farmasimed (JFM). 2026 Apr 30;8(2):668–75. doi:10.35451/8nffcw16
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Cindy Marseli, Rafifah Azzahra, Salvira Pradita, Muhammad Andry
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright in each article is the property of the Author.
